Adverum Biotechnologies Inc - Asset Resilience Ratio
Adverum Biotechnologies Inc (ADVM) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ADVM total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Adverum Biotechnologies Inc's Asset Resilience Ratio has changed over time. See Adverum Biotechnologies Inc (ADVM) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Adverum Biotechnologies Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ADVM market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Adverum Biotechnologies Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Adverum Biotechnologies Inc Industry Peers by Asset Resilience Ratio
Compare Adverum Biotechnologies Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Adverum Biotechnologies Inc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Adverum Biotechnologies Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 36.16% | $65.04 Million | $179.84 Million | +22.35pp |
| 2023-12-31 | 13.82% | $21.53 Million | $155.77 Million | -24.17pp |
| 2022-12-31 | 37.99% | $117.16 Million | $308.37 Million | -23.64pp |
| 2021-12-31 | 61.63% | $270.99 Million | $439.73 Million | -14.49pp |
| 2020-12-31 | 76.11% | $367.31 Million | $482.57 Million | +31.15pp |
| 2019-12-31 | 44.96% | $100.14 Million | $222.73 Million | +21.48pp |
| 2018-12-31 | 23.48% | $50.13 Million | $213.50 Million | -35.94pp |
| 2017-12-31 | 59.42% | $119.97 Million | $201.91 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $234.58 Million | -- |
| 2015-12-31 | 14.28% | $37.73 Million | $264.32 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $161.91 Million | -- |
About Adverum Biotechnologies Inc
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is … Read more